|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
EVANS MEDICAL PLC
Main Activities: Chemical Manufacturing - Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name EVANS MEDICAL PLC Headquarters Plot 6, Abimbola Way, Isolo P.M.B. 1120, Apapa, Lagos, Nigeria. ; Lagos; Lagos |
Status: Listed Legal Form: Other non-liability limited Operational Status: Operational ISIN CODE : NGEVANSMED04 Financial Auditors: PricewaterhouseCoopers (2010) Incorporation Date: January 1, 1979 Total Employees: 315 Tel: +(234-1)7901401-8 |
|
Company Description |
| Evans Medical Plc is one of Nigeria’s largest pharmaceutical Manufacturing Company, It started business in Nigeria in 1954 and has since then been committed to Research, Development and Manufacturing of safe and effective medicines and nutraceuticals of highest standards. Evans Medical Plc has its manufacturing facility located at Agbara in Ogun State and a Corporate Office at Isolo in Lagos State, Nigeria. The Product ranges of Evans Medical Plc are well over thirty and are household names across | ||
|
||
Company Analysis |
| According to the Consolidated - Non-Audited financial statement for the Year of 2011, total net operating revenues increased with 17.08%, from NGN 3,942,000 thousands to NGN 4,615,295 thousands. Operating Results increased from NGN -54,379 thousands to NGN 446,883 thousands. The results of the period increased 978.57% reaching NGN 94,515 thousands at the end of the period against NGN 8,763 thousands last year. Return on equity (Net income/Total equity) went from 15.16% to 243.75%, the Return On Asset (Net income / Total Asset) went from 0.21% to 2.17% and the Net Profit Margin (Net Income/Net Sales) went from 0.22% to 2.05% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 11108.35% compared to 7176.62% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 0.60 to 0.60 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 Q3C (cons) |
2011 Y (cons) |
|
 | ||
| Non-Audited | Non-Audited | |
| ||
| WVB Company Financials | WVB Company Financials | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
7,247,439 |
4,346,150 |
| ||
Current Assets |
2,790,311 |
2,602,150 |
| ||
Total Liabilities |
7,247,439 |
4,307,374 |
| ||
Shareholders Equity |
0 |
38,776 |
| ||
Current Liabilities |
2,582,894 |
4,307,374 |
| ||
| * All the accounts are in NGN. | ||
Income Statement
| ||
Total Operating Revenue |
3,514,448 |
4,615,295 |
| ||
Operational Profit (Loss) |
288,829 |
446,883 |
| ||
Net Profit (Loss) |
-107,185 |
94,515 |
| ||
| * All the accounts are in NGN. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
-1.48% |
2.17% |
| ||
Annualised Return on Assets (ROA) |
-1.97% |
2.17% |
| ||
Return on Equity (ROE) |
0% |
243.75% |
| ||
Annualised Return on Equity (ROE) |
0% |
243.75% |
| ||
Return on Sales (ROS) |
-3.08% |
2.07% |
| ||
Return on Capital |
-8.75% |
243.75% |
| ||
Gross Profit Margin |
49.17% |
47.77% |
| ||
Operating Profit Margin |
7.29% |
8.86% |
| Efficiency Ratios | ||
| ||
Accounts Receivable Turnover |
1.73x |
5.07x |
| ||
Inventory Turnover |
2.46x |
2.22x |
| ||
Current asset turnover |
1.25x |
1.76x |
| ||
Fixed-asset turnover |
0.78x |
2.62x |
| ||
Asset Turnover |
0.48x |
1.05x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
288,829 |
448,295 |
| ||
EBITDA |
288,829 |
448,295 |
| ||
Enterprise value |
2,736,310 |
1,418,130 |
| ||
Enterprise Value / EBITDA |
9.47 |
3.16 |
| ||
Bookvalue (BV) |
5,008,008 |
3,155,150 |
| ||
Net Cash |
-2,520,329 |
-4,208,567 |
| Liquidity Ratios | ||
| ||
Current Ratio |
108.03% |
60.41% |
| ||
Quick ratio |
80.23% |
35.48% |
| ||
Doom's day ratio |
2.42% |
2.29% |
| Leverage Ratios | ||
| ||
Leverage ratio |
0% |
11,208.35% |
| ||
Interest Coverage Ratio |
75.39% |
141.54% |
| ||
Debt to equity |
0% |
11,108.35% |
| ||
Debt to total assets |
100% |
99.11% |
| ||
Long Term Debt to Capital |
100% |
|
| ||
Debt / Enterprise Value |
81.84% |
83.98% |
| Market ratios | ||
| ||
Market Capitalization/EBITDA |
1.94 |
0.73 |
| ||
Price/Book Ratio |
0.12 |
0.11 |
| ||
Market Cap / Net cash |
-0.22 |
-0.08 |
| Trend Ratios | ||
| ||
Revenue Trend |
0% |
115.98% |
| ||
Net Income Trend |
0% |
1,078.57% |
| ||
Operating Income Trend |
0% |
-824.39% |
| ||
 |